The price of Quviviq (daridorexant) can vary depending on insurance coverage, pharmacy, and dosage. A 30-day supply of Quviviq 25 mg typically costs around $600, while the 50 mg dosage can range from $650 to $700 for a 30-day supply. These figures are generally for out-of-pocket expenses before insurance.
How can I get financial assistance for Quviviq?
Patients may be eligible for savings programs offered by the manufacturer, Idorsia Pharmaceuticals, which can reduce out-of-pocket costs for commercially insured individuals. The Idorsia Pharmaceuticals patient assistance program may offer support for uninsured or underinsured patients who meet certain eligibility criteria. Insurance providers may also offer coverage for Quviviq, which would significantly impact the patient's cost.
When does Quviviq's patent expire?
The patent landscape for Quviviq is complex and involves multiple patents. Understanding the exact expiration dates of all relevant patents is crucial for estimating when generic versions might become available. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can be a resource for detailed patent expiry timelines [1]. Generally, brand-name drugs are protected by patents for a period, after which generic manufacturers can seek approval to market their versions.
How does Quviviq work?
Quviviq is a dual orexin receptor antagonist that works by blocking the activity of orexin, a neurotransmitter that promotes wakefulness. By inhibiting orexin signaling, Quviviq helps to reduce the drive to stay awake, thereby facilitating sleep [2].
What is Quviviq used for?
Quviviq is prescribed for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults [2].
What are the side effects of Quviviq?
Common side effects associated with Quviviq include somnolence, headache, and fatigue [2]. Patients are advised to report any concerning side effects to their healthcare provider.
What is the difference between Quviviq and other insomnia medications?
Quviviq belongs to a class of medications called orexin receptor antagonists, which is a different mechanism of action compared to older insomnia treatments like benzodiazepines or non-benzodiazepine hypnotics (e.g., Ambien, Lunesta). Orexin receptor antagonists aim to reduce the brain's wake drive, rather than acting as general sedatives [2].
Who makes Quviviq?
Quviviq is manufactured by Idorsia Pharmaceuticals [2].
What is the clinical data supporting Quviviq?
Clinical trials have demonstrated Quviviq's efficacy in improving sleep onset and sleep maintenance in adults with insomnia. These studies typically measure endpoints such as latency to sleep onset and total sleep time [2].
What is the regulatory status of Quviviq?
Quviviq has received approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) for the treatment of insomnia in adults [2].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.quviviq.com/